Clinical trials
Myasthenia Gravis clinical trials
Below are recruiting myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 96 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07673627RecruitingPhase 2
Testing empasiprubart for generalized myasthenia gravis
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
Carlsbad, CaliforniaAges 18 years+ - NCT07294170Recruiting
Testing Multiple Treatments for Myasthenia Gravis
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Carlsbad, CaliforniaAges 18 years+ - NCT07787247Recruiting
Remote monitoring for myasthenia gravis patients
This study tests whether remote monitoring through smartphone apps can effectively track myasthenia gravis symptoms and help manage care from home, instead of frequent in-person visits.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07761026Recruiting
Living with myasthenia gravis: share your experience
This 10-year study collects information from people with myasthenia gravis to learn more about the condition and improve care. By sharing your experiences, you can help researchers understand what daily life is like and shape future treatments.
Framingham, MassachusettsAges 18 years+ - NCT06617741Recruiting
Global Registry for Myasthenia Gravis Patients
This trial is a global registry for people with myasthenia gravis (MG). It collects information to help researchers better understand MG and improve care.
Westborough, MassachusettsAges 18 years+ - NCT05337891Recruiting
Evening vs morning nerve testing in myasthenia gravis
This study compares how well a nerve test works when done in the evening versus in the morning for people with myasthenia gravis. It may help doctors choose the best time to test nerve fatigue and better measure disease activity.
Krakow, Lesser Poland VoivodeshipAges 18–80 - NCT07717281Recruiting
Studying nerve-muscle organoids for refractory myasthenia gravis
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
MilanAges 18 years+ - NCT07596901RecruitingPhase 1/Phase 2
Testing Aritinercept for Generalized Myasthenia Gravis
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
Pasadena, CaliforniaAges 18–85 - NCT07570589Recruiting
Tracking myasthenia gravis symptoms on rozanolixizumab treatment
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
Nice, Alpes-maritimesAges 18 years+ - NCT07501702RecruitingPhase 2
Study of a new drug for generalized myasthenia gravis
This study tests a new medication called povetacicept for people with generalized myasthenia gravis. The goal is to see if it can reduce muscle weakness and improve daily functioning.
Mission Hills, CaliforniaAges 18 years+ - NCT07284420RecruitingPhase 2
Testing empasiprubart with efgartigimod for myasthenia gravis
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Carlsbad, CaliforniaAges 18 years+ - NCT07250750RecruitingPhase 1/Phase 2
IM-101 for generalized and ocular myasthenia gravis
This study tests a new medicine called IM-101 in people with myasthenia gravis (MG), a muscle weakness condition. It aims to see if it can safely help manage symptoms.
Altamonte Springs, FloridaAges 18–74 - NCT07246564RecruitingPhase 4
Rozanolixizumab for Generalized Myasthenia Gravis in Chinese Adults
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
BeijingAges 18 years+ - NCT07217587RecruitingPhase 3
Comparing two drugs for generalized myasthenia gravis
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
Fullerton, CaliforniaAges 18–74 - NCT05564936Recruiting
Digital tests for generalized myasthenia gravis using a smartphone
This study tests a smartphone-based digital tool that helps check symptoms in people with generalized myasthenia gravis (MG). It may help patients and clinicians track how the disease is doing over time using simpler, repeated assessments.
Aurora, ColoradoAges 18 years+ - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT07146425Recruiting
Building a digital assessment model for myasthenia gravis
This study uses digital tools like questionnaires and smartphone tests to measure how myasthenia gravis affects you. It aims to create a better way for doctors to track your symptoms and adjust treatment.
ShanghaiAges 18 years+ - NCT07136844Recruiting
Walking and arm movement study for nerve and muscle conditions
This study uses motion analysis to understand walking and arm function in adults with certain neurological or metabolic diseases. The goal is to find patterns that help doctors better manage these conditions.
LiègeAges 18 years+ - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT06909253Recruiting
Study of ravulizumab for generalized myasthenia gravis
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
BydgoszczAges 18 years+ - NCT06860633RecruitingPhase 4
Efgartigimod for worsening myasthenia gravis in hospital
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Aurora, ColoradoAges 18 years+ - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT06491238Recruiting
Light vs. moderate exercise for myasthenia gravis
This study compares light exercise (like gentle walking) to moderate exercise (like brisk walking) for people with myasthenia gravis. It aims to see if one type of exercise is safer and more helpful for managing symptoms.
Saint Paul, MinnesotaAges 18–80 - NCT06371040RecruitingPhase 1
CAR-T cell therapy for severe myasthenia gravis
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
Xi'an, ShaanxiAges 18–80
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Myasthenia Gravis trials by city
Studies with a site in or near these metro areas.
Myasthenia Gravis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for myasthenia gravis?
- Yes. Clin2 currently lists 96 recruiting myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.